Showing 1 to 1 of 1 results
forbes.com
🌐 85% Global Worthiness
Halozyme Sues Merck Over Injectable Keytruda
Merck's new injectable Keytruda faces a lawsuit from Halozyme, delaying its planned October 1 launch and highlighting upcoming patent expirations in 2028. The suit challenges Merck's use of Halozyme's hyaluronidase technology in the new injectable formulation, and Merck has said it is meritless.
Halozyme Sues Merck Over Injectable Keytruda
Merck's new injectable Keytruda faces a lawsuit from Halozyme, delaying its planned October 1 launch and highlighting upcoming patent expirations in 2028. The suit challenges Merck's use of Halozyme's hyaluronidase technology in the new injectable formulation, and Merck has said it is meritless.
Progress
40% Bias Score
Good Health and Well-being
Showing 1 to 1 of 1 results